With FDA nod, Amgen migraine med is ready to tap pent-up demand by Eric Sagonowsky Thursday, May 17, 2018 Aimovig has several more hurdles to clear before it can reach its lofty blockbuster goals—including persuading payers it's worth the cost.
Regeneron's Eylea delivers—again—but competitive threats loom by Eric Sagonowsky Thursday, May 3, 2018 Regeneron needs some Type A newcomers to backstop its aging blockbuster Eylea, but so far, its trio of launches are still seeking traction.
Can Praluent's new formulary exclusive jump-start sales? by Eric Sagonowsky Wednesday, May 2, 2018 Regeneron and Sanofi have an exclusive PCSK9 deal with Express Scripts, but one analyst believes it's a negative for the companies.
Sanofi suffers a diabetes bloodbath by Arlene Weintraub Friday, April 27, 2018 Formulary shutouts were already hurting Sanofi's diabetes numbers. But price cuts and Medicare compounded the pain in the first quarter of 2017.
Amgen faces one-two blow from Repatha, Sensipar competition by Arlene Weintraub Tuesday, March 13, 2018 Amgen faces generic competition to its thyroid medication, Sensipar, and the potential to lose share in the PCSK9 cholesterol drug market. Now what?
Sanofi plots new push to win over payers with Praluent by Eric Sagonowsky Saturday, March 10, 2018 Sanofi and Regeneron presented Odyssey outcomes data for Praluent at ACC 2018 Saturday.
Sanofi execs say 2017 was just the beginning for Dupixent by Eric Sagonowsky Wednesday, January 10, 2018 Sanofi and Regeneron may have had a successful year with Dupixent—approved in March to treat atopic dermatitis—but there's much more to come.
Amgen's Repatha wins heart-helping FDA approval by Eric Sagonowsky Monday, December 4, 2017 Amgen has its sought-after approval to tout its PCSK9 cholesterol med Repatha as a cardiovascular prevention tool.
Medicines Co. pivots to pipeline PCSK9 med in $270M sale by Eric Sagonowsky Wednesday, November 29, 2017 The Medicines Company is going all-in on pipeline cholesterol drug inclisiran.
